Shape Memory Medical Initiates Patient Enrollment in FLAGSHIP Study of Novel False Lumen Embolization Technology Shape Memory Medical Inc. has announced a major clinical milestone with the enrollment of the first patients in its FLAGSHIP study, a first-in-human clinical trial…
Gilead Extends Tender Offer Timeline for Planned Acquisition of Arcellx Gilead Sciences, Inc. has announced an extension of its ongoing tender offer to acquire all outstanding shares of common stock of Arcellx, signaling continued progress in one of the more…
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial Evaluating BOT+BAL Combination in MSS/pMMR Metastatic Colorectal Cance Agenus Inc., a clinical-stage immuno-oncology company focused on developing novel therapies to address hard-to-treat cancers, has announced a significant milestone in…
Lilly Announces Acquisition of Centessa Pharmaceuticals to Expand Pipeline in Sleep-Wake Disorder Treatments Eli Lilly and Company and Centessa Pharmaceuticals plc have announced a definitive agreement under which Lilly will acquire Centessa in a transaction that underscores the growing strategic…
Kerendia™ Receives EU Approval for Expanded Use in Adults with Heart Failure and LVEF ≥40% Bayer has achieved a major regulatory milestone with the approval of Kerendia (finerenone) by the European Commission for an expanded indication in the European Union.…
Insulet Appoints Mike Panos as Chief Commercial Officer to Drive Global Growth of Omnipod Platform Insulet Corporation, a global leader in tubeless insulin pump technology, has announced the appointment of Mike Panos as Executive Vice President and Chief Commercial Officer.…
DiaMedica Therapeutics Reports 2025 Financial Results and Advances Clinical Pipeline in Preeclampsia and Acute Ischemic Stroke DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for serious and life-threatening conditions, has reported its financial results for the…
Phase 2 CADENCE Trial Shows Positive Results, Establishing WINREVAIR™ as a Proof-of-Concept Therapy in CpcPH and HFpEF Merck & Co.—known as MSD outside the United States and Canada—has unveiled comprehensive results from its Phase 2 CADENCE clinical trial, providing compelling…
AbbVie to Present New Clinical and Real-World Evidence Advancing Care Standards in Immune-Mediated Skin Diseases at the AAD Annual Meeting 2026 AbbVie has announced a comprehensive slate of new research findings spanning its dermatology portfolio, set to be presented at…
LEO Pharma Presents New Long-Term Data for SPEVIGO® (spesolimab-sbzo) in Adults with Generalized Pustular Psoriasis at AAD 2026 LEO Pharma A/S has announced new long-term clinical data supporting the use of SPEVIGO® (spesolimab-sbzo) in patients with generalized pustular psoriasis (GPP),…
Lantern Pharma Reaffirms Panna Sharma’s Ongoing Role as President and CEO; Warns Investors of Misleading Third-Party Report Lantern Pharma Inc., an AI-driven oncology company focused on transforming cancer drug development through its proprietary RADR® platform, has issued a formal statement…
Neurocrine Biosciences Unveils First Expert Consensus Guidelines for Managing Tardive Dyskinesia in Long-Term Care Settings Neurocrine Biosciences, Inc. today announced the presentation of the first expert consensus recommendations focused on screening, diagnosis and treatment of tardive dyskinesia among older adults in…